http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ambroise, M. Moses,Ghosh, Mitra,Mallikarjuna, V.S.,Annapurneswari, S.,Kurian, Ann,Chakravarthy, Ranjani Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.2
Background: The aim of this study was to analyze the clinicopathological and immunohistochemical features of primary central nervous system lymphoma (PCNSL) cases occurring in Indian patients and also study the utility of the crush smear preparation in intraoperative diagnosis. Materials and Methods: The immune status, clinical, radiological details, immunohistochemical profile, histopathological findings and cytological features in smear preparation of 32 cases of PCNSL were analyzed. Patients with systemic NHL and skull-base lymphomas were excluded. Results: The mean age of our patients was 52 years with a male: female ratio 1:1. A periventricular location was found in 62.5% of patients. None of our PCNSL cases were associated with AIDS. All cases except one were diffuse large B-cell lymphomas. Intraoperative diagnosis using crush smears allowed correct prediction in 93% of cases. Conclusions: Our study shows that PCNSL is seen predominantly in immunocompetent patients in India. The age of presentation is relatively young as compared to the West. Our study also stresses the utility of crush smear preparation in establishing an intraoperative diagnosis.
Fuzzy Location Algorithm for Cross-Country and Evolving Faults in EHV Transmission Line
A. Naresh Kumar,M. Chakravarthy,M. Suresh Kumar,M. Nagaraju,M. Ramesha,Bharathi Gururaj,Elemasetty Uday Kiran 한국지능시스템학회 2023 INTERNATIONAL JOURNAL of FUZZY LOGIC and INTELLIGE Vol.23 No.2
Fault protection is an important issue as it adversely affects the performance of conventional relays, particularly for cross-country and evolving faults in transmission lines. In this paper, a novel fault location algorithm for cross-country and evolving faults in extra high voltage transmission (EHVT) line using the fuzzy expert system (FES) is presented. The algorithm is based on the impedance values of relaying terminal fundamental component. In addition, the proposed FES is independent of communication links. It was designed using input variables via the IF-THEN rules and developed with the fuzzy MAMDANI structure. A triangular membership function was used to estimate the degree of inputs. MATLAB software was used to evaluate the error in the fault location for a 100-km, 400-kV, 50-Hz EHVT line. The FES algorithm yielded precise values. The test results were independent of the fault inception time, location, and type. The experimental results illustrate that the FES performed better than the other algorithms.
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Kavitha, Matam,Iravathy, Goud,Adi Maha, Lakshmi M,Ravi, V,Sridhar, K,Vijayanand, Reddy P,Chakravarthy, Srinivas,Prasad, SVSS,Tabassum, Shaik Nazia,Shaik, Noor Ahmad,Syed, Rabbani,Alharbi, Khalid Khala Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.16
Epidermal growth factor receptor (EGFR) is one of the targeted molecular markers in many cancers including lung malignancies. Gefitinib and erlotinib are two available therapeutics that act as specific inhibitors of tyrosine kinase (TK) domains. We performed a case-control study with formalin-fixed paraffin-embedded tissue blocks (FFPE) from tissue biopsies of 167 non-small cell lung carcinoma (NSCLC) patients and 167 healthy controls. The tissue biopsies were studied for mutations in exons 18-21 of the EGFR gene. This study was performed using PCR followed by DNA sequencing. We identified 63 mutations in 33 men and 30 women. Mutations were detected in exon 19 (delE746-A750, delE746-T751, delL747-E749, delL747-P753, delL747-T751) in 32 patients, exon 20 (S786I, T790M) in 16, and exon 21 (L858R) in 15. No mutations were observed in exon 18. The 63 patients with EFGR mutations were considered for upfront therapy with oral tyrosine kinase inhibitor (TKI) drugs and have responded well to therapy over the last 15 months. The control patients had no mutations in any of the exons studied. The advent of EGFR TKI therapy has provided a powerful new treatment modality for patients diagnosed with NSCLC. The study emphasizes the frequency of EGFR mutations in NSCLC patients and its role as an important predictive marker for response to oral TKI in the south Indian population.